Upper gastrointestinal adverse events and cyclical etidronate

The American Journal of Medicine
T P van StaaC Cooper

Abstract

Recently, there have been several published case reports of esophagitis associated with the use of aminobisphosphonates. The objective of this study was to evaluate the upper gastrointestinal (GI) safety of cyclical etidronate, an alkylbisphosphonate, in routine clinical practice. Information was obtained from 550 general practices in the United Kingdom that provide the medical records to the General Practice Research Database. A group of 7977 cyclical etidronate takers and 2 age-, gender-, and practice-matched control groups (1 with osteoporosis and 1 without) were analyzed. For cyclical etidronate takers, the average age was 71.6 years and total follow-up was 10,328 person-years. The risk of upper GI events (inflammation or ulcer of esophagus, stomach, or duodenum) was comparable between patients taking etidronate and the two control groups. The adjusted relative risk of upper GI events was 0.92 (95% confidence interval [CI] 0.78 to 1.09) for etidronate takers compared with osteoporosis controls and 1.12 (CI 0.91 to 1.37) compared to nonosteoporosis controls. For esophagitis and esophageal ulcers, the relative risks were 0.83 (CI 0.64 to 1.08) and 0.97 (CI 0.71 to 1.31) respectively. The incidence of upper GI events during no...Continue Reading

References

Sep 1, 1991·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·R P Heaney
Nov 16, 1984·JAMA : the Journal of the American Medical Association·M S Kramer, S H Shapiro
Mar 1, 1995·Journal of Clinical Epidemiology·Y Lis, R D Mann
Jul 3, 1993·BMJ : British Medical Journal·I NazarethS Myers
Oct 3, 1996·The New England Journal of Medicine·P C de GroenK K Wang
Oct 12, 1996·Lancet·G Naylor, M H Davies
Aug 1, 1996·Endoscopy·D SorrentinoE Bartoli
Mar 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Adami, N Zamberlan

❮ Previous
Next ❯

Citations

Nov 24, 1998·Aging : Clinical and Experimental Research·C Gennari, J Y Reginster
Jan 9, 2014·BMC Gastroenterology·Arianna GhirardiUNKNOWN AIFA-BEST Investigators
Nov 30, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M TadrousS M Cadarette
Feb 1, 2002·Aging : Clinical and Experimental Research·J D AdachiE Gomez-Panzani
Dec 19, 2013·PloS One·Arianna GhirardiUNKNOWN BEST Investigators
Aug 9, 2003·Expert Opinion on Drug Safety·John K Marshall
Aug 9, 2003·Expert Opinion on Drug Safety·Ian R Reid
Oct 11, 2002·Mayo Clinic Proceedings·Byron Cryer, Douglas C Bauer
Mar 13, 2002·Mayo Clinic Proceedings·Hugh TaggartKaren P Stevens
Mar 10, 2001·American Journal of Physical Medicine & Rehabilitation·T IkaiS Miyano
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Pfeilschifter, I J Diel
Jul 6, 2000·Journal of Endocrinological Investigation·S AdamiR Balena
Aug 30, 2003·Expert Opinion on Drug Safety·Karl-Uwe Petersen, Daniel Jaspersen
Mar 17, 2020·Current Osteoporosis Reports·Alison M BoyceCarlos R Ferreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.